Other Clinical Trial - Impact of Melatonin in the Pretreatment of Organ

Status Not yet recruiting

Clinical Trial Summary

Impact of melatonin on organ donor pretreatment and liver transplant recipient: prospective, randomized, double-blind trial.

OBJECTIVES. To establish the efficacy of the melatonin administered to encephalic death donors (EDD) in liver transplantation. The aim is to improve the functional quality of the retrieved organs, attenuate lesions and ischemia-reperfusion mediators, and provide grafts with greater resistance to post-transplant aggression.

METHODOLOGY. Prospective, randomized, double-blind, pilot trial to evaluate preconditioning with melatonin versus placebo in EDDs. Two groups, melatonin and control-placebo, n=30 per group. Administration to donor via NG tube of 30mg of melatonin or placebo (lactose) upon inclusion in the trial, 60 minutes prior to commencement of surgery and following laparotomy during extraction. Evaluation of response to treatment: A) Conventional clinical, hemodynamic, analytical and histopathological parameters in donor and recipient. B) Plasma determinations for: oxidative/nitrosative stress; acute phase proteins; cellular and humoral immunity; NT-proBNP and cystatin C; endocrine profile; melatonin levels. C) Determinations in liver tissue: quantification of malonyldialdehyde-4hydroxyalkenals and protein carbonyl content; cellular and mitochondrial membrane fluidity; markers of tissue-vascular damage and proliferation: transforming growth factor-beta (TGF-β); hypoxia-inducible factor (HIF) and vascular endothelial growth factor (VEGF). Data will be analyzed following a prospectively define plan and by intention-to-treat analysis.

Clinical Trial Description

This study will be done in the Hospital Clinico Lozano Blesa (Zaragoza, Spain), promoted by the Health Science Aragon Institute and its principal investigator is F. Agustín García Gil (Surgical Service). It will start in April-May 2013 and will finish 12 months later approximately. The study sponsor is I+CS (Aragon Institute of Health Sciences). ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

Evidence of Liver Transplantation

Clinical Trial Details

NCT number	NCT01860716
Study type	Interventional
Source	Aragon Institute of Health Sciences
Contact
Status	Not yet recruiting
Phase	Phase 3
Start date	May 2013
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02239991` - Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant	N/A
Recruiting	`NCT03013634` - Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation	N/A
Active, not recruiting	`NCT02579408` - Quantifying Steatosis in Liver Transplant Donors
Completed	`NCT02008097` - Clinical Benefits of B-Flow Ultrasound	N/A
Completed	`NCT04763096` - Evaluate the Efficacy and Safety of the ADVAGRAF®	Phase 4
Recruiting	`NCT01766518` - The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)	Phase 4
Recruiting	`NCT01607788` - Prospective Liver Tumor (ProLiT) Database	N/A
Completed	`NCT01022476` - Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients	Phase 1/Phase 2
Completed	`NCT01546064` - Study to Establish Whether the Use of T-Tube in Bile Duct Anastomosis in Liver Transplantation Decreases Morbidity	N/A
Completed	`NCT02263703` - Immunogenicity of HPV Vaccine in Immunosuppressed Children	Phase 3
Terminated	`NCT00473824` - Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation	Phase 2
Terminated	`NCT00151632` - Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation	Phase 3
Active, not recruiting	`NCT02350218` - Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)	Phase 2
Completed	`NCT02608606` - Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors	N/A
Recruiting	`NCT02451046` - Usefulness of Alpha-GST in Liver Transplantation	N/A
Completed	`NCT00177931` - Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit	N/A
Completed	`NCT01147380` - Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation	Phase 1
Terminated	`NCT00694408` - A Pilot Trial of Pediatric Liver Transplantation Without Steroids	Phase 3
Terminated	`NCT00375895` - Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation	Phase 3
Recruiting	`NCT01157403` - Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms